Page 291 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Compound heterozygous DPYD variant allele carriers
References
1. Scrip’s Cancer Chemotherapy Report. Scrip world pharmaceutical news London: PJB Publications Ltd. 2002.
2. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23-44.
3. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine,
UFT, S-1): a review. Oncologist. 2002;7(4):288-323.
4. Rosmarin D, Palles C, Pagnamenta A, et al. A candidate gene study of capecitabine-related toxicity
in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather
than TYMS. Gut. 2015;64(1):111-120.
5. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and
2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-
analysis. Pharmacogenomics. 2013;14(11):1255-1272.
6. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to
fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of
CALGB 89803. J Clin Oncol. 2007;25(23):3456-3461.
7. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of
5-fluorouracil. Eur J Cancer. 2004;40(7):939-950.
8. Gonzalez FJ, Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis
of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci. 1995;16(10):325-327.
9. van Kuilenburg ABP, Meijer J, Maurer D, et al. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and
mRNA splicing. Biochim Biophys Acta. 2017;1863(3):721-730.
10. Meulendijks D, Henricks LM, van Kuilenburg AB, et al. Patients homozygous for DPYD c.1129-
5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated
with fluoropyrimidines. Cancer Chemother Pharmacol. 2016;78(4):875-880.
11. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase
activity. Cancer Res. 2014;74(9):2545-2554.
12. Henricks LM, Lunenburg CATC, Meulendijks D, et al. Translating DPYD genotype into DPD
phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16(11):1277-1286.
13. Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize
Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016;34(3):227-234.
14. Lunenburg CATC, van Staveren MC, Gelderblom H, Guchelaar HJ, Swen JJ. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated
patients. Pharmacogenomics. 2016;17(7):721-729.
15. Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation
of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol.
2018;19(11):1459-1467.
16. Lunenburg CATC, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the
risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 2016;54:40- 48.
11
289